Member Info for Titania

"Fewer participants required hospitalisation following treatment with SNG001 (N=1/110, [1%]) compared to placebo (N=7/110, [6%]), an 86% relative risk reduction, that was not statistically significant (P=0.07; two-sided Fisher's exact test). There were no deaths in either arm."

Just thinking the 1% hospitalised on SNG001 was within 3% expected high viral rebound rate.

https://pubmed.ncbi.nlm.nih.gov/36802755/

"We need to take into account this baseline rate of symptom and viral rebound when interpreting reports of rebound after Paxlovid and other antiviral therapies. "

Did they make this adjustment when interpreting SNG001 Activ2 report?

"3% high level viral rebound"
https://twitter.com/DrJLi/status/1628635658410684416/photo/1

We are grateful to the
@ACTGNetwork
ACTIV-2 participants and study team, including Kara Chew,
@DaveySmithMD, @Dr_Carlee_Moser, @joseph_eron
, Judy Currier, Eric Daar, Michael Hughes, and our co-authors! 13/13

Liking the words "rapidly" and "multiple".

"This marks the launch of STRIVE, developed under #ACTIV, to rapidly assess multiple therapeutics for respiratory diseases:"

https://twitter.com/NIHDirector/status/1625998970014273536
Sorry if already posted.

https://twitter.com/CarlosdelRio7/status/1628188641041465345?cxt=HHwWgoDSiam8vpgtAAAA

Kara Chew from Activ2 speaking later on about further developments for mild and moderate Covid.

15 Oct 2022 a tweet by Prasanna Jagannathan
Excited to (finally!) share our manuscript! Can the early immune response to SARS-CoV-2 infection predict clinical and long-term immunological outcomes? Amazing work led by
@ZichengHu in collab with many at Stanford and UCSF (1/4)

https://elifesciences.org/articles/77943

Apologies if already posted.

“It appears that interferon responses triggered by some respiratory viruses can block SARS-CoV-2 infection,” says Dr. Murcia.

https://www.physiciansweekly.com/rsv-influenza-hinder-sars-cov-2-replication-within-respiratory-epithelium/

Apologies if already posted.

https://twitter.com/BARDA/status/1625102875046060032/photo/1

Could this be a trial possibility for SNG001?

https://www.colliers.com/en-ie/properties/12-13-fitzwilliam-place/irl-dublin-2-d02-vn56/irl58000406

"CEO Pascal Soriot said the firm was on a path to deliver at least 15 new medicines this decade and said it expects to kick off at least thirty new late-stage clinical trials in 2023."

https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-q4-revenue-just-shy-analyst-estimates-2023-02-09/

https://pharmaboardroom.com/articles/top-10-global-pharma-companies-2022/

Not out the question for SNG001 to be used prophylactically for flu,Covid-19,RSV and HRV?
85% down from the placing price and we may well be the focus of their strategy! The fourth largest pharma in the world!!

"Moving forward, J&J plans to focus on pre-exposure prophylaxis to flu, COVID-19, RSV and HRV, the slides show."

https://www.fiercepharma.com/pharma/johnson-johnson-quietly-works-through-global-overhaul-layoffs-spreading-multiple-countries

Lets hope they push hard to recover the purchase value of their investment and that long term holders are rewarded as well.

https://www.tetragoninv.com/wp-content/uploads/2022/07/Tetragon-2022-Half-Yearly-Report.pdf

P23: 90 million $ loss biotechnology exposure!

Agreed! But right now the company for what ever reason has not managed to hustle themselves onto a platform trial. Therefore why not do a submission to try another route to a
trial possibility. The gate keepers might be slightly different for that route. Answer could be no you need to be on a platform trial first! Are we even having these sorts of discussions?

The Government themselves are saying new clinical trials are not feasible given the rate of SARS-CoV-2 evolution.

I hope Synairgen will study this document carefully and develop a multi-pronged approach to our situation. Given what is said in this government document I personally do not believe a submission based on all our evidence and post hoc analysis is out the question! They should be requesting the variant isolates to show the continued effectiveness of SNG001!
They could well be successful with the provisor that we are continuously revalidated on an appropriate platform trial!